Depomed to Acquire U.S. Rights to NUCYNTAÂ® (tapentadol), NUCYNTAÂ® ER (tapentadol) extended release tablets and NUCYNTAÂ® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for $1.05 billion